Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
HISTORY
Where we began and why there’s no end in sight.

MediBeacon, in a management buyout in 2012, acquired technology from Mallinckrodt/Covidien.

The company’s intellectual property has expanded substantially and now includes over 55 US patents, which cover composition of matter of the company’s pharmaceuticals, as well as devices, algorithms, processes, and methods related to the transdermal detection of these patented fluorescent agents.

MediBeacon is a medical technology company focused on advancing fluorescent tracer agents and transdermal detection technology to provide vital and actionable measurement of organ function.

Measurements of organ function at the point of care have the potential to provide information that will help healthcare providers to fundamentally change the standard of care in numerous clinical situations. It is our mission to provide doctors with information that empowers them to make better decisions faster.

Focus is on enabling more timely intervention.

Our advancements in fluorescent tracer agent technology aim to give medical practitioners accurate physiological assessments at the point of care in a hospital, physicians‘ office, or at a patient‘s home.

The value of transdermal detection of organ function depends upon the manner in which physicians employ the information provided by these systems. MediBeacon hopes to provide tools which may help physicians improve the care that they provide to patients.

LIMITLESS POSSIBILITIES
Shining new light on physiological measurement.

We believe there are no limits to our thinking or what that thinking can accomplish.
Advances in the development of biocompatible fluorescent tracer agents that can be detected by a sensor placed on the skin are at the core of MediBeacon’s scalable medical technology platform. The solutions are designed to be clinically practical, relevant, and easily understood.

Point of care GFR assessment has the potential to provide clinicians information at the bedside to manage their patients with kidney disease more accurately and rapidly.

Transdermal GI permeability measurement has the potential to be a tool that could help doctors to evolve their understanding of mucosal healing in a way that can impact the proactive care of those with inflammatory bowel diseases and a range of other autoimmune disorders.

Improvements in ocular and surgical visualization are other possible future uses of the florescent tracer technology.

Preclinical use of fluorescent tracer agent-based monitoring systems are having an impact.

Our preclinical product enables researchers to measure kidney function in a streamlined and accurate manner. Over 600 peer-reviewed publications and conference abstracts describe the ground breaking research in which the transdermal measured GFR technique has been used. Improvements in preclinical research techniques have the potential to reduce the time it takes to get lifesaving treatments and pharmaceuticals from ideation to commercialization.*

Forward-Looking Statements
Statements on this website may include forward-looking statements within the meaning of certain securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.